Enabling E-Biotech
Executive Summary
Approached creatively, the Web offers biotechs a distribution medium for the selling of expertise as expertise, rather than as therapeutic products, and its application to many problems, not a specific few. Such a strategy is directly contradictory to a biotech model built around exclusive collaborations. But the Web-enabled possibility of selling expertise broadly changes the biotech's customer base. Where biotechs currently look to sell a few, high-cost deals in which most of the funding comes at the end of a highly risky project, the Web-biotech sells to many subscribers who pay up front.
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.